NewAmsterdam Pharma Co N.V.

NAMS Nasdaq SEC CIK 1936258
Follow NewAmsterdam Pharma Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $19.2M +5406.9% vs same quarter last year
Net income −$17.4M +75.9% vs same quarter last year
EPS, diluted −$0.14 +77% vs same quarter last year
Operating cash flow −$39.8M −21.4% vs same quarter last year
Revenue by quarter
$12.8M
$3M
$19.1M
$348K
$32K
$3M
$3.7M
$19.2M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income6 fiscal years
  • Revenue
  • Net income
−$300M−$200M−$100M$0$100M$200MFY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$22.5M−$203M
FY24$45.6M−$242M
FY23$14.1M−$177M
FY22$102.7M−$22.6M
FY21-−$41.8M
FY20--
MarginsShare of revenue
  • Operating margin
  • Net margin
−1500%−1000%−500%0%FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−1002.9%−902.1%
FY24−386.9%−531.1%
FY23−1298.6%−1256.2%
FY22−3.5%−22%
FY21--
FY20--
Free cash flowOperating cash flow minus capital expenditure
−$200M−$150M−$100M−$50M$0$50MFY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$148M
FY24−$159.2M
FY23−$141.2M
FY22$10.4M
FY21−$29.5M
FY20-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • NewAmsterdam Pharma
  • Healthcare median
−1500%−1000%−500%0%FY20FY21FY22FY23FY24FY25
Show the numbers
YearNewAmsterdam PharmaHealthcare median
FY25−902.1%−30.6%
FY24−531.1%−47%
FY23−1256.2%−58%
FY22−22%−80.4%
FY21-−71.9%
FY20-−62.2%